Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-20
2009-06-16
Richter, Johann R (Department: 1619)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S469000, C514S654000, C514S659000, C514S909000, C514S910000
Reexamination Certificate
active
07547723
ABSTRACT:
The comprehensive pharmacologic therapy for treatment of obesity is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and/or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.
REFERENCES:
patent: 3097947 (1963-07-01), Kemmerer
patent: 4237118 (1980-12-01), Howard
patent: 4377595 (1983-03-01), Wurtman
patent: 4397866 (1983-08-01), Wurtman
patent: 4596807 (1986-06-01), Crosby
patent: 5019594 (1991-05-01), Wurtman et al.
patent: 5084007 (1992-01-01), Malin et al.
patent: 5189064 (1993-02-01), Blum et al.
patent: 5480657 (1996-01-01), Allen
patent: 5502080 (1996-03-01), Hitzig
patent: 5527788 (1996-06-01), Svec et al.
patent: 5650438 (1997-07-01), Meier et al.
patent: 5716976 (1998-02-01), Bernstein
patent: 5795895 (1998-08-01), Anchors
patent: 5939076 (1999-08-01), Allocca
patent: 5977076 (1999-11-01), Anderson et al.
patent: 5977099 (1999-11-01), Nickolson
patent: 6048728 (2000-04-01), Inlow et al.
patent: 6132724 (2000-10-01), Blum
patent: 6207699 (2001-03-01), Rothman
patent: 6261589 (2001-07-01), Pearson et al.
patent: 6323236 (2001-11-01), McElroy
patent: 6335323 (2002-01-01), Worsley
patent: 6384088 (2002-05-01), Hinz
patent: 6403657 (2002-06-01), Hinz
patent: 6548551 (2003-04-01), Hinz
patent: 6660777 (2003-12-01), Hinz
patent: 6759437 (2004-07-01), Hinz
patent: 7268161 (2007-09-01), Hinz
patent: 2001/0002269 (2001-05-01), Zhao
patent: 2001/0008641 (2001-07-01), Krotzer
patent: 2001/0008884 (2001-07-01), Worsley
patent: 2001/0020007 (2001-09-01), Wiss
patent: 2002/0040054 (2002-04-01), Hinz
patent: 2002/0147206 (2002-10-01), Howard, Jr.
patent: 2002/0187958 (2002-12-01), Horrobin et al.
patent: 2003/0181509 (2003-09-01), Hinz
patent: 2004/0071681 (2004-04-01), Muller
patent: 2004/0077556 (2004-04-01), Chinery
patent: 2004/0081678 (2004-04-01), Cincotta
patent: 2004/0101575 (2004-05-01), Hinz
patent: 2004/0116351 (2004-06-01), Halevic-Goldman
patent: 2004/0151771 (2004-08-01), Gin et al.
patent: 2004/0229285 (2004-11-01), Hinz
patent: 2004/0247669 (2004-12-01), Gin et al.
patent: 2005/0065190 (2005-03-01), Hinz
patent: 2005/0233008 (2005-10-01), Hinz
patent: 2005/0233014 (2005-10-01), Lee et al.
patent: 2005/0287226 (2005-12-01), Sisco et al.
patent: 2006/0062859 (2006-03-01), Blum et al.
patent: 0347066 (1989-12-01), None
patent: 2137493 (1984-10-01), None
patent: 410067663 (1998-03-01), None
patent: WO 01/26642 (2001-04-01), None
U.S. Appl. No. 09/523,114, filed Mar. 10, 2000, Hinz.
U.S. Appl. No. 11/353,644, filed Feb. 14, 2006, Hinz.
U.S. Appl. No. 11/353,643, filed Feb. 14, 2006, Hinz.
Agúndez et al, “Modulation of CyP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine”,Pharmacogentics, 8:251-258 (1998).
Andrews et al, “The Effects of 5-hydraoxytryptophan and 5-hydroxytryptamine on Dopamine Synthesis and Release in Rat Brain Striatal Synaptosomes”,Journal of Neurochemistry, 30:465-470 (1978).
Avarello, “Serotonin Syndrome: a reported case”,Neuro Sci, 23:S55-S56 (2002).
Bartholome et al., “L-dopa and 5-hydroxytryptophan Therapy in Phenylalanine-Hydroxylase Activity”,The Lancet2(Nov. 22): 1042-1043 (1975).
Bouyer et al., “Modification of Spontaneous ECoG and Behavior in Cat by Monoamine Precursors”,Psychopharmacology, 65:49-54 (1979).
Coppen et al. “Levodopa and L-tryptophan Therapy in Parkinsonism”,The Lancet, Mar. 25, 1972.
Dunner et al., “Affective Disorder: Studeis with Amine Precursors”,Am J. Psychiatry, 132(2):180-183 (1975).
Gelenberg et al. “Tyrosine for the treatment of depression”,Nutr. Health, 3(3):163-73 (1984).
Hurley et al., Pyrrolo[1,4]benzodiazepine Antibiotics. Biosynthesis of the Antitumr Antibiotic 11-Demethyltomaymycin and its Biologically Inactive metabolity Oxotomaymycin toStreptomyces achromogene, Biochemistry, 15(17):3760-3769 (1976).
Kramarcy et al, “Effects of Drug-Inducted Changes in Brian Monoamines on Aggression and Motor Behavior in Mice”,European Journal of Pharmacology, 99:141-151 (1984).
Li Kam Wa et al., “Renal metabolism and effects of the glutamyl derivates of L-dopa and 5-dydroxytryptophan in man”,Clinical Science, 91:177-185 (1996).
Lindström et al., “Aromatic amino acids and pancreatic islet function: a comparison of L-tryptophan and L-5-hydroxytryptophan”,Molecular and Cellular Endocrinology, 48:121-126 (1986).
Lindström, “Aromatic-L-Amino-Acid Decarboxylase Activity in Mouse Pancreatic Islets”,Biochimica et Biophysica Acta, 884: 276-281 (1986).
Malone et al., “Treatment (Rx) of 76 Pateitns with Primary Fibromyalgia (1° FM) with Combined Dopaminergic and Serotonergic Drugs”, Arthritis & Rhuematism, 39:S92 (1996) (Abstract).
Mathiau et al, “Absence of Serotonergic Innervation from Raphe Nuclie in Rat Cerebral Blood Bessesl—II. Lack of Trypthophan Hydroxylase Activity In Vitro”Neuroscience, 52(3): 657-665 (1993).
Meyers, “Use of Neurotranmitter Precursors for Treatment of Depression”,Alternative Medicine Review, 5(1):64-71 (2000).
Niedens et al, “First fungal aromatic L-amino acid decarboxylase from a paclitaxel-producingPenicillium raistrickii”,Mycologia, 91(4):61-26 (1999) (Abstract).
Rabey et al., “L-trypotphan Administration in L-Dopa-Induced Hallucinations in Elderly Parkinsonian Patients” Gerontology, 23:438-444 (1977).
Sawaki et al., “Some correlations between Procaine-Induces Convulsions and Monamines in the Spinal Cord of Rats”,Japan, J. Pharmacol, 51:369-376 (1989).
Schlosberg et al., “Effects of L-Dopa and L-5-Hydroxytryptophan on Locomotor Activity of the Rat after Selective or combined destruction of Central Catecholamine and Serotonin Neurons”,The Journal of Pharmacology and Experimental Therapeutics, 211(2):296-304 (1979).
Shintaku et al., “Diagnosis and treatment of 6-pyruvoyl-tetrahydropterin synthase deficience”,Brain&Development, 22:S118-S121 (2000).
Sternberg et al, “Development of Scleroderma-like Illness during Therapy with L-5-hydroxytryptophan and Carbidopa”,The New England Journal of Medicine, 303(14):782-787 (1980).
Tanaka et al., “Hyperphenylalaninemia Due to Impared Dihydrobiopterin Biosynthesis”,Eur. J. Pediatr, 136:275-280 (1981).
Thurmond et al, “Effects of Dietary Tyronsine, Phenylamlanine, and Tryptophan on Aggression in Mice”,Pharmacoogy Biochemistry&Behavior, 6:475-478 (1977).
Trulson et al., “Behavorial Effect of Serotonergic and Dopaminergic Drugs in Cats Following Chronic Amphetamine Administration”,European Journal of Pharmacology, 99:313-324 (1984).
Weitbrecht and et al., “Der Einfluss von 1-Tryptophan auf die L-Dopa-Resportion”,Dtsch Med Wochenschr, 101(1): 20-22 (1976).
Dave Peterson Affidavit (Apr. 11, 2005).
U.S. Appl. No. 11/282,965, filed Nov. 18, 2005, Hinz.
Praag, H.M., “In Search of the Mode of Action of Antidepressants 5-HTP/Tyrosine Mixtures in Depressions”,Neuropharmacology, vol. 22, No. 3B, pp. 433-440, 1983.
Budavari et al.;The Merck Index; Merck & Co., Inc.; 1989, 11thEdition, p. 2321, and 4116.
Donald Heath; Pulmonary Vascular Disease;Medical Clinics of North America, vol. 61/No. 6, Nov. 6, 1997, Symposium on Pulminary disease, pp. 1279-1307.
Jules Hirsch; The Treatment of Obesity with Drugs;The American journal of Clinical Nutrition, Jan. 1998, pp. 2-4.
Griffen, MD, et al.; Asy
Lea Christopher R
Richter Johann R
Vidas Arrett & Steinkraus
LandOfFree
Comprehensive pharmacologic therapy for treatment of a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Comprehensive pharmacologic therapy for treatment of a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Comprehensive pharmacologic therapy for treatment of a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4143880